PRO 140 350mg weekly subcutaneous (SC) injection.

Drug identity checked against registry records

Also recorded as PRO 140

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
An Extension of Protocol PRO 140_CD01 StudyNCT02355184CytoDyn, Inc.Phase 2Terminated2022-06Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.